S1418/BR006 A Randomized Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy.

Brief description of study

If you have been diagnosed with triple negative breast cancer (TNBC) you may qualify to participate in a clinical trial investigating the investigational drug MK-3475. The main purpose of this study is to see if immunotherapy with MK-3475 (pembrolizumab) can lower the risk of recurrence in patients with triple negative breast cancer who have residual cancer identified in the surgical specimen after standard chemotherapy.

Clinical Study Identifier: s16-02231

ClinicalTrials.gov Identifier: NCT02954874

Principal Investigator: Sylvia Adams.

Other Investigators: Elliot M. Belenkov, Maryann J Kwa, Yelena Novik, Franco M Muggia, Marleen I Meyers, Ruth Oratz, James L Speyer.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies